P1111 Two Years on Linaclotide: Tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea
Author insight from William D. Chey, MD, FACG, University of Michigan, Ann Arbor, MI
What’s new here and important for clinicians?
- In an 18 month long term safety study which included over 500 IBS-C patients, 32% reported diarrhea as an adverse event.
- The diarrhea was reported to be mild (47%) to moderate (47%) in 94% of patients.
- Over half reported their diarrhea in the first 2 weeks of treatment.
- 76% of those reporting diarrhea either reduced their dose and/or suspended treatment but only 3% (17/535) withdrew from the study as a result of diarrhea.
- Patients with and without a diarrhea adverse event (AE) reported similar levels of satisfaction with linaclotide therapy.
What do patients need to know?
Diarrhea is the most common side effect with linaclotide – it is usually mild to moderate in severity and tends to happen within a couple of weeks of initiating therapy. Severe diarrhea is rare.
Author Contact
William D. Chey, MD, FACG, University of Michigan, Ann Arbor, MI
wchey@umich.edu
Related Abstracts
Oral 12 Analysis of Exhaled Volatile Organic Compounds Reveals New Biomarkers for Irritable Bowel Syndrome
P506 Understanding Gender Differences in IBS: The Role of Stress From the Social Environment
P1719 Regional Variation of Care for Irritable Bowel Syndrome in the United States
P1718 Age-Related Health Care Disparities in Patients With Irritable Bowel Syndrome: Findings From a Sample of Commercially Insured Patients
P1110 Cognitive Behavioral Self-Help for Irritable Bowel Syndrome
P1117 What Strategies Do Patients With Irritable Bowel Syndrome Continue to Use Following a 9-Week Comprehensive Self-Management Program?
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.